DNTH PE Ratio & Valuation, Is DNTH Overvalued

Historical Valuation

Dianthus Therapeutics Inc (DNTH) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1683.31 is considered Overvalued compared with the five-year average of -7.79. The fair price of Dianthus Therapeutics Inc (DNTH) is between 9.26 to 61.27 according to relative valuation method. Compared to the current price of 85.84 USD , Dianthus Therapeutics Inc By Overvalued By 40.09%.

Relative Value

Fair Zone

9.26-61.27

Current Price：85.84

40.09%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Dianthus Therapeutics Inc (DNTH) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Dianthus Therapeutics Inc (DNTH) has a current Price-to-Book (P/B) ratio of 3.11. Compared to its 3-year average P/B ratio of 2.01, the current P/B ratio is approximately 55.02% higher. Relative to its 5-year average P/B ratio of 2.01, the current P/B ratio is about 55.02% higher. Dianthus Therapeutics Inc (DNTH) has a Forward Free Cash Flow (FCF) yield of approximately -6.44%. Compared to its 3-year average FCF yield of -10.57%, the current FCF yield is approximately -39.04% lower. Relative to its 5-year average FCF yield of -10.57%, the current FCF yield is about -39.04% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for DNTH competitors is 392.96, providing a benchmark for relative valuation. Dianthus Therapeutics Inc Corp (DNTH.O) exhibits a P/S ratio of 1683.31, which is 328.36% above the industry average. Given its robust revenue growth of -78.58%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of DNTH increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of DNTH in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is DNTH currently overvalued or undervalued?

Dianthus Therapeutics Inc (DNTH) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1683.31 is considered Overvalued compared with the five-year average of -7.79. The fair price of Dianthus Therapeutics Inc (DNTH) is between 9.26 to 61.27 according to relative valuation method. Compared to the current price of 85.84 USD, Dianthus Therapeutics Inc is Overvalued By 40.09%.

What is Dianthus Therapeutics Inc (DNTH) fair value?

DNTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Dianthus Therapeutics Inc (DNTH) is between 9.26 to 61.27 according to relative valuation method.

How does DNTH's valuation metrics compare to the industry average?

The average P/S ratio for DNTH's competitors is 392.96, providing a benchmark for relative valuation. Dianthus Therapeutics Inc Corp (DNTH) exhibits a P/S ratio of 1683.31, which is 328.36% above the industry average. Given its robust revenue growth of -78.58%, this premium appears unsustainable.

What is the current P/B ratio for Dianthus Therapeutics Inc (DNTH) as of Mar 12 2026?

As of Mar 12 2026, Dianthus Therapeutics Inc (DNTH) has a P/B ratio of 3.11. This indicates that the market values DNTH at 3.11 times its book value.

What is the current FCF Yield for Dianthus Therapeutics Inc (DNTH) as of Mar 12 2026?

As of Mar 12 2026, Dianthus Therapeutics Inc (DNTH) has a FCF Yield of -6.44%. This means that for every dollar of Dianthus Therapeutics Inc's market capitalization, the company generates -6.44 cents in free cash flow.

What is the current Forward P/E ratio for Dianthus Therapeutics Inc (DNTH) as of Mar 12 2026?

As of Mar 12 2026, Dianthus Therapeutics Inc (DNTH) has a Forward P/E ratio of -10.23. This means the market is willing to pay $-10.23 for every dollar of Dianthus Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Dianthus Therapeutics Inc (DNTH) as of Mar 12 2026?

As of Mar 12 2026, Dianthus Therapeutics Inc (DNTH) has a Forward P/S ratio of 1683.31. This means the market is valuing DNTH at $1683.31 for every dollar of expected revenue over the next 12 months.

DNTH Valuation